Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients

Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nefrología 2001-03, Vol.21 (2), p.167-173
Hauptverfasser: Armada, E, Pérez Melón, C, Otero, A, Gayoso, P, Rodríguez, M, Esteban Morcillo, J
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173
container_issue 2
container_start_page 167
container_title Nefrología
container_volume 21
creator Armada, E
Pérez Melón, C
Otero, A
Gayoso, P
Rodríguez, M
Esteban Morcillo, J
description Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p < 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p < 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p < 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p < 0.05). After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71019757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71019757</sourcerecordid><originalsourceid>FETCH-LOGICAL-p540-9fae4bb4c4b29a1586169e4654ae0eac3d2abdfbd82567dd3735945462d7f6b3</originalsourceid><addsrcrecordid>eNo1kEtLAzEcxHNQbK1-BcnJ20KSzaM5SqkPKPSgJy9LHv_QSHazbrJCv70LVhiYy_yGYa7QmjBKG6m1WKHbUr4IkYJpdYNWlHLJpSBr9LkPAVzFOeCQU3TYuOhxmccxQQ9DNTXmAS-quZqET7nP7lwqxAFwgh9IBccBn6DPPpp0LrHgcWEWstyh62BSgfuLb9D78_5j99ocji9vu6dDMwpOGh0McGu545ZpQ8VWUqlhGccNEDCu9cxYH6zfMiGV961qheaCS-ZVkLbdoMe_1nHK3zOU2vWxOEjJDJDn0ilKqFZCLcGHS3C2PfhunGJvpnP3_0X7CwQCW8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71019757</pqid></control><display><type>article</type><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</creator><creatorcontrib>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</creatorcontrib><description>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p &lt; 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p &lt; 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p &lt; 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p &lt; 0.05). After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</description><identifier>ISSN: 0211-6995</identifier><identifier>PMID: 11464650</identifier><language>spa</language><publisher>Spain</publisher><subject>Aged ; Drug Resistance ; Female ; Folic Acid - administration &amp; dosage ; Folic Acid - blood ; Folic Acid - therapeutic use ; Homocysteine - blood ; Humans ; Hyperhomocysteinemia - complications ; Hyperhomocysteinemia - drug therapy ; Hyperhomocysteinemia - epidemiology ; Hyperhomocysteinemia - prevention &amp; control ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Pyridoxine - administration &amp; dosage ; Pyridoxine - therapeutic use ; Renal Dialysis ; Serum Albumin - analysis ; Spain - epidemiology ; Treatment Outcome ; Urea - blood ; Vitamin B 12 - blood</subject><ispartof>Nefrología, 2001-03, Vol.21 (2), p.167-173</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11464650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armada, E</creatorcontrib><creatorcontrib>Pérez Melón, C</creatorcontrib><creatorcontrib>Otero, A</creatorcontrib><creatorcontrib>Gayoso, P</creatorcontrib><creatorcontrib>Rodríguez, M</creatorcontrib><creatorcontrib>Esteban Morcillo, J</creatorcontrib><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><title>Nefrología</title><addtitle>Nefrologia</addtitle><description>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p &lt; 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p &lt; 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p &lt; 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p &lt; 0.05). After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</description><subject>Aged</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Folic Acid - administration &amp; dosage</subject><subject>Folic Acid - blood</subject><subject>Folic Acid - therapeutic use</subject><subject>Homocysteine - blood</subject><subject>Humans</subject><subject>Hyperhomocysteinemia - complications</subject><subject>Hyperhomocysteinemia - drug therapy</subject><subject>Hyperhomocysteinemia - epidemiology</subject><subject>Hyperhomocysteinemia - prevention &amp; control</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Pyridoxine - administration &amp; dosage</subject><subject>Pyridoxine - therapeutic use</subject><subject>Renal Dialysis</subject><subject>Serum Albumin - analysis</subject><subject>Spain - epidemiology</subject><subject>Treatment Outcome</subject><subject>Urea - blood</subject><subject>Vitamin B 12 - blood</subject><issn>0211-6995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEcxHNQbK1-BcnJ20KSzaM5SqkPKPSgJy9LHv_QSHazbrJCv70LVhiYy_yGYa7QmjBKG6m1WKHbUr4IkYJpdYNWlHLJpSBr9LkPAVzFOeCQU3TYuOhxmccxQQ9DNTXmAS-quZqET7nP7lwqxAFwgh9IBccBn6DPPpp0LrHgcWEWstyh62BSgfuLb9D78_5j99ocji9vu6dDMwpOGh0McGu545ZpQ8VWUqlhGccNEDCu9cxYH6zfMiGV961qheaCS-ZVkLbdoMe_1nHK3zOU2vWxOEjJDJDn0ilKqFZCLcGHS3C2PfhunGJvpnP3_0X7CwQCW8g</recordid><startdate>200103</startdate><enddate>200103</enddate><creator>Armada, E</creator><creator>Pérez Melón, C</creator><creator>Otero, A</creator><creator>Gayoso, P</creator><creator>Rodríguez, M</creator><creator>Esteban Morcillo, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200103</creationdate><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><author>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p540-9fae4bb4c4b29a1586169e4654ae0eac3d2abdfbd82567dd3735945462d7f6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2001</creationdate><topic>Aged</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Folic Acid - administration &amp; dosage</topic><topic>Folic Acid - blood</topic><topic>Folic Acid - therapeutic use</topic><topic>Homocysteine - blood</topic><topic>Humans</topic><topic>Hyperhomocysteinemia - complications</topic><topic>Hyperhomocysteinemia - drug therapy</topic><topic>Hyperhomocysteinemia - epidemiology</topic><topic>Hyperhomocysteinemia - prevention &amp; control</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Pyridoxine - administration &amp; dosage</topic><topic>Pyridoxine - therapeutic use</topic><topic>Renal Dialysis</topic><topic>Serum Albumin - analysis</topic><topic>Spain - epidemiology</topic><topic>Treatment Outcome</topic><topic>Urea - blood</topic><topic>Vitamin B 12 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armada, E</creatorcontrib><creatorcontrib>Pérez Melón, C</creatorcontrib><creatorcontrib>Otero, A</creatorcontrib><creatorcontrib>Gayoso, P</creatorcontrib><creatorcontrib>Rodríguez, M</creatorcontrib><creatorcontrib>Esteban Morcillo, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nefrología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armada, E</au><au>Pérez Melón, C</au><au>Otero, A</au><au>Gayoso, P</au><au>Rodríguez, M</au><au>Esteban Morcillo, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</atitle><jtitle>Nefrología</jtitle><addtitle>Nefrologia</addtitle><date>2001-03</date><risdate>2001</risdate><volume>21</volume><issue>2</issue><spage>167</spage><epage>173</epage><pages>167-173</pages><issn>0211-6995</issn><abstract>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p &lt; 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p &lt; 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p &lt; 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p &lt; 0.05). After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</abstract><cop>Spain</cop><pmid>11464650</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0211-6995
ispartof Nefrología, 2001-03, Vol.21 (2), p.167-173
issn 0211-6995
language spa
recordid cdi_proquest_miscellaneous_71019757
source MEDLINE; Alma/SFX Local Collection
subjects Aged
Drug Resistance
Female
Folic Acid - administration & dosage
Folic Acid - blood
Folic Acid - therapeutic use
Homocysteine - blood
Humans
Hyperhomocysteinemia - complications
Hyperhomocysteinemia - drug therapy
Hyperhomocysteinemia - epidemiology
Hyperhomocysteinemia - prevention & control
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Middle Aged
Prevalence
Prospective Studies
Pyridoxine - administration & dosage
Pyridoxine - therapeutic use
Renal Dialysis
Serum Albumin - analysis
Spain - epidemiology
Treatment Outcome
Urea - blood
Vitamin B 12 - blood
title Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A57%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20folic%20acid%20supplementation%20on%20total%20homocysteine%20levels%20in%20hemodialysis%20patients&rft.jtitle=Nefrolog%C3%ADa&rft.au=Armada,%20E&rft.date=2001-03&rft.volume=21&rft.issue=2&rft.spage=167&rft.epage=173&rft.pages=167-173&rft.issn=0211-6995&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71019757%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71019757&rft_id=info:pmid/11464650&rfr_iscdi=true